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Abstract
Objective Anecdotally, the Brockenbrough transseptal nee-
dle generates plastic particles through a process of skiving
(shaving off particles), when advanced through the dilator
and sheath. This study was performed to assess particle
creation by the Brockenbrough needle during transseptal
catheterization. We explore strategies that may reduce this
phenomenon, including use of the Brockenbrough stylet
and a radiofrequency transseptal needle.
Method In vitro simulations of transseptal catheterization
were performed using Brockenbrough transseptal needles
and a new radiofrequency transseptal needle. Particles that
were created during advancement of transseptal needles
through the sheath and dilator were collected and analyzed.
Particles in the visible range of 50 μm to 4 mm were
identified using a light microscope, whereas particles in the
sub-visible, yet clinically relevant range of 10 to 50 μm,
were counted using a light obscuration method.
Results All simulated procedures using the Brockenbrough
transseptal needles, with or without a stylet, generated
visible particles. Simulated procedures with the radiofre-
quency transseptal needle generated no visible particles. A
greater number of sub-visible particles were generated with
the standard Brockenbrough transseptal needle (BKR-1)
without stylet compared with the standard Brockenbrough
needle (BRK-1) with stylet, the Brockenbrough extra sharp
(BRK-1XS) needle with or without stylet, and the radio-
frequency needle (NRG C1).
Conclusion Clinically relevant particles, both visible and
sub-visible, with the potential for causing embolic complica-
tions, are generated by the BRK-1 needle without stylet. Use
of a stylet in the BRK-1 needle, or the BRK-1XS needle with
or without stylet, appears to reduce the size and amount of
particles created. The NRG C1 needle appears to eliminate
visible particles and is comparable to the BRK-1 with stylet
and the BRK-1XS with or without stylet in generation of sub-
visible particles. Important steps can be taken to minimize the
creation of particles during the advancement of the BRK-1
through the transseptal sheath and dilator.
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1 Background
T transseptal catheterization is the technique of choice for
left atrial access for the treatment of several conditions.
Ross et al. pioneered the transseptal technique in the 1960s
[1]. Brockenbrough described a refined technique in 1962
[2]. Since then, there has been little variation in the
technique [3].
Earley et al. describe the transseptal procedure in greater
detail [4]. Central to the transseptal procedure is a sharp-
tipped needle, commonly referred to as the Brockenbrough
needle, which is used in combination with a sheath and
dilator. There are two common techniques used to load the
Brockenbrough needle into the dilator, one with the stylet
in place and one with the stylet removed. Elimination of the
stylet with connection of the needle to a pressure transducer
directly before advancing it through the dilator may speed
up the procedure. However, this exposes the sharp tip of the
needle as it is advanced through the dilator.
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Recently, the number of transseptal catheterization
procedures performed annually has increased as a result
of an increase in left-sided procedures such as atrial
fibrillation ablation. Despite the relative safety of this
procedure, there are still potential complications associ-
ated with the technique, which include cardiac tampo-
nade, air embolism, and thromboembolism due to clot
formation or tissue charring during ablation [5]. Throm-
boembolism due to a previously unreported cause may
also result from the creation of plastic particles that are
scraped off the inner wall of the transseptal dilator by the
Brockenbrough transseptal needle as it is advanced
through the dilator.
Awareness of the risk of creating particles first emerged
at our center during a routine transseptal catheterization
procedure. After left atrial access had been successfully
achieved, contrast media could not be injected through the
Brockenbrough needle. We therefore removed the needle,
and while maintaining the position of the tip of the dilator
inside the left atrium, we attempted to advance a guidewire
through the dilator into the left atrium. However, the
guidewire could not be advanced through the dilator either.
This required that the dilator be removed from the sheath,
and when the dilator was flushed, a large piece of shaved
plastic was ejected from the lumen, which it had been
obstructing.
Particles introduced into the circulatory system may pose
a risk to patient health. Particles as small as 15–50 μm can
obstruct the microvascular bed causing microinfarcts and
left ventricular dysfunction [6]. A known standard for
assessing the risk from particles is the United States
Pharmacopeia USP 788 “Particulate matter in injections,”
which illustrates that particles that are greater than 10 μm in
size pose a clinically significant risk to patient health, and
particles that are greater than 25 μm pose a high risk to the
patient. [6–8]
The objectives of this study were to measure the creation
of skived particles through in vitro testing of two common
Brockenbrough transseptal needles, to evaluate if certain
techniques or device features had an impact on the creation
of particles, and to evaluate a new radiofrequency trans-
septal needle [9], to determine if its rounded distal tip had
an impact on the creation of particles.
2 Methods
2.1 Device selection
Three transseptal needles were tested as shown in Fig. 1.
The needles all had similar distal curves so as to allow for a
direct comparison of the test results. One model of sheath
and dilator was used for the study.
The tests for visible particles were conducted with the
BRK-1 and BRK-1XS Brockenbrough needles (St. Jude,
Inc., Minneapolis, MN) and the NRG C1 RF needle (Baylis
Medical, Inc., Montreal, QC, Canada). Both the BRK-1 and
the BRK-1XS were tested with and without a stylet. The
BRK-1 needle has a bevel that is in-line with the curve of
needle whereas the BRK-1XS has a bevel that is opposite to
the curve of the needle. Both needles were tested to
determine if the bevel orientation has an impact on particle
generation. The RG C1 RF needle has a closed rounded tip
with two side holes located 2 mm from the distal tip
through which pressure is measured and contrast is injected,
and therefore, does not accept a stylet. All tests were
conducted using a new #8-French Daig SL-1 transseptal
sheath and dilator (St. Jude, Inc., Minneapolis, MN).
2.2 Transseptal procedure simulation
All devices tested were sterile, and previously unused. While
it is assumed that sterile products come completely particle-
free out of the package, this is not always the case as there may
be sub-visible particles present. For this reason, particle-free
saline was flushed through each sterile sheath kit, and over
and through each needle to clean away preexisting sub-visible
particles. The flushed fluid was captured and measured to
establish a baseline sub-visible particle measurement for each
set of devices. There were no visible particles present on any
devices tested prior to their use.
The introducer sheath was inserted into 3/8” clear vinyl
tubing to mimic the constraints that the vasculature imposes
Fig. 1 Transseptal needles evaluated from left to right are the BRK-1,
BRK-1XS, NRG-C1
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upon the introducer kit. Two sets of tests were conducted,
one to determine the creation of visible particles which are
greater than 50 um, and one to determine the creation of
clinically significant sub-visible particles which are in the
range of 10 to 50 um.
Tests for the visible particles consisted of advancing the
needle back and forth three times through the sheath and
dilator followed by flushing the assembly. The resulting
solution was filtered through millipore filter paper (47 mm,
0.8 um, black grid, Type AA) and allowed to dry in air.
Each filter was examined using a reflected light compound
microscope following the microscopic particle count test as
described in the United States Pharmacopeia USP 788
guidance document. Visible particles were photographed
using a Zeiss Stereo Microscope.
The tests for the sub-visible particles (10 μm to 50 μm)
used a similar approach. The needle was advanced back and
forth three times through the sheath and dilator, after which
the assembly was flushed and the resulting solution was
captured for measurement. In order to reduce the chance of
particulate leftover during packaging from affecting the
results of the study comparison, the dilators and sheaths
were thoroughly flushed with sterile saline (8–10 cm3) prior
to testing. Each solution suspension was degassed for 2 min
prior to analysis. Measurements of the sub-visible particles
were conducted using the light obscuration method, by
means of a HIAC Royco Particle Counter. The light
obscuration method consists of passing the solution through
a laser beam. Particles obscure the laser beam during its
transit through the solution and the total laser light minus
the light obscured by the particles is used by a particle
counter to count and size the particles. Each sample was
measured four times using a sample volume of 5 mL. The
data from the first measurement was discarded and the
average of the last three samples is reported. This method is
described in the United States Pharmacopeia USP 788
guidance document.
2.3 Statistical analysis
Statistical analysis of the difference in means in the sub-
visible particle counts (Table 1) was performed using a
one-way ANOVA with Bonferroni correction for multiple
comparisons with SPSS statistical software package
(SPSS, Inc., Chicago, IL).
3 Results
Skived particles were created by the tip of the Brocken-
brough needle scraping against the inner wall of the dilator
as it was advanced. Scraping was felt through the
Brockenbrough needle as an increase in resistance or a
grinding sensation during needle advancement. This resis-
tance was particularly noticeable at two sites, (1) when the
needle is advanced through the proximal solid hub of the
sheath and dilator and (2) when the needle navigates the
distal curve of the sheath and dilator. The solid hub of the
sheath and dilator imposes a narrow, noncompliant channel
in which the curved needle is forcibly straightened. The
preset curve at the distal end of the sheath and dilator tip
also presents a place where the needle not only actively
scrapes the inner wall, but also where in extreme cases it
may puncture the sheath and dilator.
There were four separate tests conducted with the
Brockenbrough needle, (1) BRK-1 without stylet, (2)
BRK-1 with stylet, (3) BRK-1XS without stylet, and (4)
BRK-1XS with stylet, all of which generated visible
particles. The procedure performed with the NRG C1
radiofrequency needle did not generate any visible par-
ticles. Visible particles were found on the outer surface of
the Brockenbrough needles, occluding their lumens, and in
saline flushed through the dilators after the needles were
removed. Particles found on the outer surfaces or flushed
from the dilators appeared like twisted lengths of ribbon
(Fig. 2). Particles occluding the lumen had the appearance
of cylindrical plugs, similar to what might be generated by
a biopsy needle (Fig. 3). Interestingly, Wong et al. reported
using a transseptal needle specifically for the purpose of
liver biopsy [10]. Figure 4 illustrates a variety of particles
formed by the Brockenbrough needles during the proce-
dure. Particles measured as large as 6 mm in length (when
untwisted), and over 0.3 mm in width. The BRK-1 needle
without stylet produced the largest size particles. Figure 4
also illustrates that there were no visible particles created by
the RF needle.
The BRK-1 needle without a stylet generated a
significantly greater number of sub-visible particles
(Table 1) compared with the BRK-1 needle with stylet,
the BRK-1XS needle with or without stylet, or the NRG
C1 radiofrequency needle (p<0.01 for BRK-1 without
stylet vs. all others).
Table 1 Light obscuration results for sub-visible particles 10–50 μm
BRK-1 without stylet BRK-1 with stylet BRK-1XS without stylet BRK-1XS with stylet NRG C1
Post-procedure particle count 50.4±1.49* 12.9±2.25 10.8±0.67 15.6±1.1 17.2±2.9
*p<0.01 for BRK-1 without stylet vs. BRK-1 with stylet, BRK-1XS with or without stylet, and NRG C1 using one-way ANOVAwith Bonferroni
correction for multiple comparisons
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4 Discussion
Unlike other complications associated with transseptal
catheterization procedures, the introduction of particles
can be asymptomatic at first, particularly if the patient is
sedated or under general anesthesia. When signs or
symptoms of a systemic embolic event are finally recog-
nized, they are typically attributed to thromboembolism,
rather than particle embolization [11, 12]. Clinical experi-
ence and the bench-top testing in this report confirm the
generation of particles that could potentially cause an
embolism during transseptal catheterization procedures.
Systemic embolism has long been considered a Major
Adverse Cardiac Event during angioplasty [6–8].
As with any needle designed to puncture the atrial
septum with mechanical force, sharpness is critical for the
needle to be effective. There is a direct trade-off however
between the sharpness of the needle required to make the
puncture and the degree to which it scrapes off particles
from the inner wall of the dilator through which it is
advanced to perform the puncture. New developments in
needle tip design have recently become available, focusing
on bevel orientation (BRK-1XS) and rounded atraumatic
tips (NRG C1). In this study, the BRK-1XS had mixed
results, with no impact on the creation of visible particles,
while reducing the amount of sub-visible particles com-
pared with the standard BRK-1 needle. The NRG C1
needle, which uses radiofrequency energy to create the
transseptal puncture, appears to eliminate the creation of
visible particles and is comparable with the BRX-1XS
needle with or without a stylet and BRX-1 needle with
stylet in creating very few sub-visible particles.
In addition to specific needle selection, several other
strategies can be used to minimize the creation of particles
during transseptal needle advancement through the sheath
and dilator. First, it is important that the needle be allowed
to rotate freely within the dilator as it is advanced through
the tortuous route imposed by the venous system, particu-
larly in the pelvic area. Failure to allow for this rotation,
which may be up to 360° in some cases, increases the
chance that the tip of the Brockenbrough needle will scrape
against the inner lumen of the dilator, thereby increasing the
possibility of skiving of plastic particles or, in extreme
cases, puncturing through the dilator and sheath wall. The
use of a stylet with the BRK-1 needle did not eliminate
visible particles, but did reduce the amount of the sub-
visible particles created when compared with the tests done
without the stylet. However, this approach results in the need
to aspirate the needle to eliminate air once deployed in the
sheath, which is difficult in some cases because of a lack of
airtight seal between the needle and dilator. It is also common
practice in some centers to flush the transseptal needle during
or after its advancement into the dilator, but prior to transseptal
puncture. Flushing the needle in the right atrium may expel
particles prior to crossing into the left atrium where they pose
a potentially greater risk, but it is not known what adverse
effect this may have on the pulmonary circulation long term. It
may also be beneficial to flush the needle as it is advanced past
the hub and the curve in the sheath and dilator. Another
technique that some practitioners employ, in an effort to
loosen and expel particles that may be susceptible to skiving,
is to repeatedly insert and remove the needle from the dilator
in order to scrape out and clear the inner lumen, while the
needle/dilator assembly is outside the body. The needle/dilator
assembly, attached to a pressure transducer, is then inserted
into the transseptal sheath, which is already positioned in the
right atrium prior to transseptal puncture.
Practitioners frequently need to re-shape the curve of the
available transseptal needles depending on the anatomy of
the patient so as to better engage the inter-atrial septum.
Currently, needles with larger curves are available, which
eliminate the need for reshaping. But in either case, if the
needle is reshaped with a larger curve or a large curve
needle is required to perform the transseptal puncture, this
will increase the forces applied by the tip of the needle as it
is advanced through the dilator against the inner lumen,
which in turn may increase the risk of skiving particles.
Fig. 3 Cored particle in the visible range
Fig. 2 Shaved particle in the visible range
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5 Study limitations
It was beyond the scope of this study to examine all
potential combinations of Brockenbrough needles, trans-
septal sheaths, and dilators. The BRK-1 and BRK-1XS
needles were chosen for testing along with the Daig
SL-1 introducer kit because of their widespread use. The
NRG C1 radiofrequency needle was chosen for testing as
it offers a rounded atraumatic tip. It is acknowledged
that there are a number of other suppliers of Brocken-
brough needles, sheaths, and dilators. Different needles
may be more or less sharp, may have a more or less
acute curve, and may have a stiffer or softer shaft than
those tested, which in turn could result in variations on
the creation of particles. As well, the size and suppleness
of the sheath and dilator can also be expected to have an
impact. A more compliant sheath and dilator may result
in less particle creation, whereas a stiffer sheath and
dilator may result in greater particle creation. Therefore,
the results and conclusions may not be extrapolated to
all devices currently available. In a clinical setting, the
sheath and dilator are physically constrained by the
vasculature that changes with respect to each patient’s
anatomy. Thus, it is possible that during clinical use a
sheath and dilator may be more or less compliant and
perhaps more or less prone to skiving than observed
during the experimental conditions in this study. A small
sample size of devices was used in this study, which
may have limited to some extent the statistical analysis
of the data.
Fig. 4 Various visible particles
observed following three inser-
tions with each needle type
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6 Conclusions
The Brockenbrough needle creates clinically significant
visible particles when advanced through a transseptal
sheath and dilator. This is true whether the standard stylet
is used or not. However, the use of a stylet with the BRK-1
needle or a BRK-1XS needle with or without stylet was
effective in reducing the number of clinically significant
sub-visible particles. The NRG C1 radiofrequency needle,
with a rounded atraumatic tip, does not create any clinically
significant visible particles and very few sub-visible
particles when advanced through a transseptal sheath and
dilator.
As the dangers of embolization during transseptal
catheterization are well-known, additional steps may
need to be taken to mitigate the risk of particle creation.
It is important that the needle be allowed to rotate
within the dilator as it is advanced as this alleviates the
pressure of the needle against the inner wall of the
dilator. Reaming the dilator with the needle outside the
body and loading the needle/dilator assembly as a single
unit into the sheath may also reduce the amount of
particles introduced into the body. Further evaluation of
the various needle, sheath, and dilator combinations
used at any specific institution for potential skiving of
particles could be done prior to transseptal catheteriza-
tion as well.
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